MW GE Healthcare's business grows with boost from imaging and diagnostic drug units

By Steve Gelsi

Medical-technology company's revenue falls slightly short of estimate, but adjusted profit beats target.

GE Healthcare Technologies Inc. on Thursday topped analysts' expectations for adjusted profit as its business benefited from growth in its ultrasound imaging products and diagnostic drug products.

GE Healthcare $(GEHC)$ said its fourth-quarter adjusted earnings rose to $1.45 a share from $1.18 a share in the year-ago period.

The company topped the FactSet consensus estimate of $1.26 a share.

GE Healthcare's (GEHC) fourth-quarter revenue grew by 2% to $5.32 billion, compared with the analyst estimate of $5.33 billion, with contributions from the company's pharmaceutical-diagnostics and advanced-visualization-solutions units.

The company's net income margin increased to 13.5% in the fourth quarter, from versus 7.7% for the prior year, with the benefit of better productivity and volume.

"We were pleased with the strong momentum in orders, backlog and book-to-bill that we saw in the fourth quarter," Chief Executive Peter Arduini said in a prepared statement. "Customer interest in new, differentiated products contributed to orders growth and recurring revenue in the year."

For full-year 2025, GE Healthcare Technologies expects adjusted earnings of $4.61 a share to $4.75 a share, compared with the analyst estimate of $4.66 a share.

GE Healthcare Technologies' stock was down 1.3% on Wednesday.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 13, 2025 07:03 ET (12:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.